Exploratory plasma ctDNA genomic biomarkers identified by whole-exome sequencing and a novel bioinformatics pipeline in advanced driver-negative NSCLC.

doi:10.1038/s41598-026-55868-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Exploratory plasma ctDNA genomic biomarkers identified by whole-exome sequencing and a novel bioinformatics pipeline in advanced driver-negative NSCLC.

Scientific reports - 30 May 2026

Posado-Domínguez Luis, López-Gutiérrez Álvaro, Del Barco Morillo Edel, Redondo-González Juan Carlos, Hernández-Pérez Marco, Egido-Iglesias Noelia, Canal-Alonso Ángel, Corvo-Félix Laura, Rodríguez-Françoso Aline, Bellido-Hernández Lorena, Fonseca-Sánchez Emilio, Cruz-Hernández Juan Jesús, Corchado Juan Manuel, García Hernández Juan Luis, Olivares-Hernández Alejandro

Abstract excerpt

Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced non-small-cell lung cancer (NSCLC), but predictive biomarkers remain suboptimal. Blood-based tumour mutational burden (bTMB) captures part of the signal, yet its clinical performance is inconsistent. Whole-exome sequencing (WES) of plasma-derived ctDNA, analysed through an automated, AI-enabled platform (AIRGenomics), may reveal broader...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to Circulating Tumor DNA

Share to Computational Biology

Share to Exome Sequencing

Share to Genomics

Share to Lung Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42218277
DOI: 10.1038/s41598-026-55868-0
PMCID: PMC13458506

Genes

CYP4F2
TPSB2
ARSD
ALK
CEP89
EGFR
KMT2C
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploratory plasma ctDNA genomic biomarkers identified by whole-exome sequencing and a novel bioinformatics pipeline in advanced driver-negative NSCLC.PMID 42218277Read ↗

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.Semantic proximity Read ↗

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome ConsortiumSemantic proximity Read ↗

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotypingSemantic proximity Read ↗

AI enabled exome and transcriptome liquid biopsy platform spanning the continuum of care in oncologySemantic proximity Read ↗

Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung CancerSemantic proximity Read ↗

Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.Semantic proximity Read ↗

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene PanelSemantic proximity Read ↗

Longitudinal Whole-Exome Sequencing of Cell-Free DNA Reveals Molecular Evolution and Heterogeneous Clinical Outcomes in PD-L1 Stratified Advanced NSCLC Adenocarcinoma Patients Treated with Atezolizumab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.